Technical Analysis for LNTH - Lantheus Holdings, Inc.

Grade Last Price % Change Price Change
A 67.39 1.28% 0.85
LNTH closed up 1.28 percent on Wednesday, May 1, 2024, on 1.66 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: May 2
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Reversal New Highs Setup Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
NR7 Range Contraction 1.28%
Inside Day Range Contraction 1.28%
Overbought Stochastic Strength 1.28%
Crossed Above 200 DMA Bullish 0.19%

   Recent Intraday Alerts

Alert Time
Up 3% about 5 hours ago
Up 1 ATR about 5 hours ago
Rose Above Upper Bollinger Band about 7 hours ago
Up 2% about 7 hours ago
60 Minute Opening Range Breakout about 9 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lantheus Holdings, Inc. Description

Lantheus Holdings, Inc. is engaged in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company's medical imaging agents are used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. The Company's products include contrast agents and medical radiopharmaceuticals, including technetium generators. The Company's products include DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, Neurolite, Thallium Tl 201, Gallium Ga 67, Gludef, Quadramet and Ablavar. The Company is also engaged in developing agents, such as Flurpiridaz F 18, which is a myocardial perfusion imaging agent; 18F LMI 1195, which is a cardiac neuronal imaging agent, and LMI 1174, which is a vascular remodeling imaging agent.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Disease Chemical Elements Prostate Cancer Heart Failure Medical Imaging Stroke Medical Physics Artery Perfusion Artery Disease Imaging Agent Peripheral Vascular Disease Radiopharmaceuticals Congestive Heart Failure Coronary Artery Disease Gallium Neuron Cardiovascular And Other Diseases Medicinal Radiochemistry Myocardial Perfusion Imaging

Is LNTH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 100.8505
52 Week Low 50.2
Average Volume 888,682
200-Day Moving Average 65.31
50-Day Moving Average 62.11
20-Day Moving Average 62.86
10-Day Moving Average 65.08
Average True Range 2.08
RSI (14) 68.35
ADX 30.21
+DI 34.25
-DI 7.66
Chandelier Exit (Long, 3 ATRs) 62.77
Chandelier Exit (Short, 3 ATRs) 64.41
Upper Bollinger Bands 67.95
Lower Bollinger Band 57.76
Percent B (%b) 0.94
BandWidth 16.21
MACD Line 1.72
MACD Signal Line 1.19
MACD Histogram 0.5282
Fundamentals Value
Market Cap 4.62 Billion
Num Shares 68.5 Million
EPS 1.50
Price-to-Earnings (P/E) Ratio 44.93
Price-to-Sales 3.21
Price-to-Book 5.51
PEG Ratio 0.61
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 72.08
Resistance 3 (R3) 72.10 70.56 71.30
Resistance 2 (R2) 70.56 69.37 70.55 71.04
Resistance 1 (R1) 68.98 68.63 69.77 68.95 70.78
Pivot Point 67.43 67.43 67.83 67.42 67.43
Support 1 (S1) 65.85 66.24 66.64 65.83 64.00
Support 2 (S2) 64.31 65.50 64.29 63.74
Support 3 (S3) 62.72 64.31 63.48
Support 4 (S4) 62.70